Is immunotherapy an opportunity for effective treatment of drug addiction?

Vaccine

Volumn 33, Issue 48, 2015, Pages 6545-6551

  Zalewska Kaszubska, Jadwiga ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Addiction; Antibody; Cocaine; Methamphetamine; Nicotine; Opioid; Phencyclidine; Vaccine

Indexed keywords

COCAINE; DRUGS USED IN THE TREATMENT OF ADDICTION; METHAMPHETAMINE; MONOCLONAL ANTIBODY; NICOTINE VACCINE; OPIATE; PHENCYCLIDINE; DIAMORPHINE; NICOTINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; BLOOD BRAIN BARRIER; COCAINE DEPENDENCE; DRUG DEPENDENCE; HEROIN DEPENDENCE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; METHAMPHETAMINE DEPENDENCE; NONHUMAN; OPIATE ADDICTION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; MALE; PROCEDURES; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VACCINATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COCAINE; FEMALE; HEROIN; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; MALE; NICOTINE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VACCINATION;

EID: 84951569653     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.079     Document Type: Review

References (89)

1. Haney M., Kosten T.R. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004, 3:11-18.
2. Kosten T., Owens S.M. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005, 108:76-85.
3. Meijler M.M., Matsushita M., Wirsching P., Janda K.D. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004, 1:77-89.
4. Montoya I.D. Advances in the development of biologics to treat drug addictions and overdose. Adicciones 2012, 24:95-103.
5. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin Pharmacol Ther 2012, 91:60-70.
6. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196-1204.
7. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35:2031-2040.
8. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008, 3:e2547.
9. Martell B.A., Mitchell E., Poling J., Gonsai K., Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58:158-164.
10. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Gardner T., Kosten T.R. Substance abuse vaccines. Ann NY Acad Sci 2008, 1141:257-269.
11. Pentel P.R., Malin D.H., Ennifar S., Hieda Y., Keyler E., Lake J.R., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuate its behavioral and cardiovascular effect in rats. Pharmacol Biochem Behav 2000, 65:191-198.
12. Brimijoin S., Shen X., Orson F., Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013, 12:323-332.
13. Shen X., Kosten T.R. Immunotherapy for drug abuse. CNS Neurol. Disord Drug Targets 2011, 10:876-879.
14. Carroll M.E., Gao Y., Brimijoin S., Anker J.J. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl) 2011, 213:817-829.
15. Gentry W.B., Ruedi-Bettschen D., Owens S.M. Anti-(+) methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 2010, 88:390-393.
16. Zheng F., Zhan C.G. Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications. Future Med Chem 2009, 1:515-528.
17. Wainer B.H., Fitch F.W., Fried J., Rothberg R.M. A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. J Immunol 1973, 110:667-673.
18. Bonese K.F., Wainer B.H., Fitch F.W., Rothberg R.M., Schuster C.R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974, 252:708-710.
19. Killian A., Bonese K., Rothberg R.M., Wainer B.H., Schuster C.R. Effects of passive immunization against morphine on heroin self-administration. Pharmacol Biochem Behav 1978, 9:347-352.
20. Raleigh M.D., Pravetoni M., Harris A.C., Birnbaum A.K., Pentel P.R. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther 2013, 344:397-406.
21. Stowe G.N., Schlosburg J.E., Vendruscolo L.F., Edwards S., Misra K.K., Schulteis G., et al. Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol Disord Drug Targets 2011, 10:865-875.
22. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24:3232-3240.
23. Li Q.Q., Luo Y.X., Sun C.Y., Xue Y.X., Zhu W.L., Shi H.S., et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem. 2011, 119:1271-1281.
24. Pravetoni M., Raleigh M.D., Le Naour M., Tucker A.M., Harmon T.M., Jones J.M., et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012, 30:4617-4624.
25. Schlosburg J.E., Vendruscolo L.F., Bremer P.T., Lockner J.W., Wade C.L., Nunes A.A., et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci USA 2013, 110:9036-9041.
26. Kantak K.M., Collins S.L., Lipman E.G., Bond J., Giovanoni K., Fox B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000, 148:251-262.
27. Kantak K.M., Collins S.L., Bond J., Fox B.S. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) 2001, 53:334-340.
28. Heading C.E. TA-CD. Xenova. IDrugs 2002, 5:1070-1074.
29. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66:1116-1123.
30. Orson F.M., Rossen R.D., Shen X., Lopez A.Y., Wu Y., Kosten T.R. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 2013, 22:69-174.
31. Kosten T.R., Domingo C.B., Hamon S.C., Nielsen D.A. DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett 2013, 541:29-33.
32. Kosten T.R., Domingo C.B., Shorter D., Orson F., Green C., Somoza E., et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014, 140:42-47.
33. Hicks M.J., De B.P., Rosenberg J.B., Davidson J.T., Moreno A.Y., Janda K.D., et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011, 19:612-619.
34. Wee S., Hicks M.J., De B.P., Rosenberg J.B., Moreno A.Y., Kaminsky S.M., et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2012, 37:1083-1091.
35. Maoz A., Hicks M.J., Vallabhjosula S., Synan M., Kothari P.J., Dyke J.P., et al. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology 2013, 38:2170-2178.
36. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010, 67:59-65.
37. Treweek J.B., Janda K.D. An antidote for acute cocaine toxicity. Mol Pharm 2012, 9:969-978.
38. Norman A.B., Ball W.J. Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody. Immunotherapy 2012, 4:335-343.
39. Baird T.J., Deng S.X., Landry D.W., Winger G., Woods J.H. Natural and artificial enzymes against cocaine I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 2000, 295:1127-1134.
40. Cai X., Whitfield T., Hixon M.S., Grant Y., Koob G.F., Janda K.D. Probing active cocaine vaccination performance through catalytic and noncatalytichapten design. J Med Chem 2013, 56:3701-3709.
41. Deng S.X., de Prada, Landry D.W. Anticocaine catalytic antibodies. J Immunol Methods 2002, 269:299-310.
42. Mets B., Winger G., Cabrera C., Seo S., Jamdar S., Yang G., et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 1998, 95:10176-10181.
43. Briscoe R.J., Jeanville P.M., Cabrera C., Baird T.J., Woods J.H., Landry D.W. A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis. Int Immunopharmacol 2001, 1:1189-1198.
44. Brecht M.L., Mayrhauser von C., Anglin M.D. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs 2000, 32:211-220.
45. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
46. Cruickshank C.C., Montebello M.E., Dyer K.R., Quigley A., Blaszczyk J., Tomkins S., et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008, 27:326-333.
47. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., et al. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
48. Moreno A.Y., Mayorov A.V., Janda K.D. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011, 133:6587-6595.
49. Miller M.L., Moreno A.Y., Aarde M., Creehan K.M., Vandewater S.A., Vaillancourt B.D., et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 2013, 73:721-728.
50. Miller M.L., Aarde S.M., Moreno A.Y., Creehan K.M., Janda K.D., Taffe M.A. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend 2015, (Epub ahead of print) (Jun 19. pii: S0376-8716(15)00313-0). 10.1016/j.drugalcdep.2015.06.014.
51. Shen X.Y., Kosten T.A., Lopez A.Y., Kinsey B.M., Kosten T.R., Orson F.M. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013, 129:41-48.
52. Rüedi-Bettschen D., Wood S.L., Gunnell M.G., West C.M., Pidaparthi R.R., Carroll F.I., et al. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 2013, 31:4596-4602.
53. Stevens M.W., Tawney R.L., West C.M., Kight A.D., Henry R.L., Owens S.M. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs 2014, 6:547-555.
54. Laurenzana E.M., Stevens M.W., Frank J.C., Hambuchen M.D., Hendrickson H.P., White S.J., et al. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother 2014, 10:2638-2647.
55. Stevens M.W., Henry R.L., Owens S.M., Schutz R., Gentry W.B. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs 2014, 6:1649-1656.
56. Cahill K., Stevens S., Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013, 5:CD009329.
57. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000, 22:809-819.
58. Lindblom N., de Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002, 69:254-260.
59. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Ann Re Pharmacol Toxicol 2009, 49:57-71.
60. Benowitz N.L. Nicotine addiction. N Engl J Med 2010, 362:2295-2303.
61. Nashmi R., Lester H.A. CNS localization of neuronal nicotinic receptors. J Mol Neurosci 2006, 30:181-184.
62. Conti D.V., Lee W., Li D., Liu J., Van Den Berg D., Thomas P.D., et al. Pharmacogenetics of nicotine addiction and treatment consortium: nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008, 17:2834-2848.
63. Maskos U., Molles B.E., Pons S., Besson M., Guiard B.P., Guilloux J.P., et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005, 436:103-107.
64. Picciotto M.R., Zoli M., Rimondini R., Léna C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
65. Esterlis I., Hannestad J.O., Perkins E., Bois F., D'Souza D.C., Tyndale R.F., et al. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry 2013, 170:399-407.
66. Hatsukami D.K., Rennard S., Jorenby D., Fiore M., Koopmeiners J., de Vos A., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005, 78:456-467.
67. Wagena E.J., de Vos A., Horwith G., van Schayck C.P. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008, 10:213-218.
68. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89:392-399.
69. Fahim R., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. CNS Neurol Expert Rev Vaccines 2013, 12:333-342.
70. Nabi Biopharmaceuticals: News Release. Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial. http://phx.corporate-ir.net/phoenix.zhtml?c=100445%26p=irol-newsArticle%26ID=1626882.
71. Hoogsteder P.H., Kotz D., van Spiegel P.I., Viechtbauer W., van Schayck O.C. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction 2014, 109:1252-1259.
72. Havermans A., Vuurman E.F., van den Hurk J., Hoogsteder P., van Schayck O.C. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Addiction 2014, 109:1260-1267.
73. Tonstad S., Heggen E., Giljam H., Lagerbäck P.Å., Tønnesen P., Wikingsson L.D., et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013, 15:1492-1501.
74. Selecta Biosciences Recent news. Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention 〈〉. http://www.selectabio.com/news/recent-news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm.
75. De Villiers S.H., Cornish K.E., Troska A.J., Pravetoni M., Pentel P.R. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 2013, 31:6185-6193.
76. Rosenberg J.B., De B.P., Hicks M.J., Janda K.D., Kaminsky S.M., Worgall S. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Hum Gene Ther 2013, 24:595-603.
77. Hu Y., Zheng H., Huang W., Zhang C. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. Hum Vaccin Immunother 2014, 10:64-72.
78. Cornish K.E., Harris A.C., LeSage M.G., Keyler D.E., Burroughs D., Earley C., et al. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol 2011, 11:1809-1815.
79. Roiko S.A., Harris A.C., Keyler D.E., Lesage M.G., Zhang Y., Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 2008, 325:985-993.
80. Domino E.F., Luby E.D. Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr Bull 2012, 38:914-919.
81. Owens S.M., Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986, 14:52-58.
82. Valentine J.L., Owens S.M. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 1996, 278:717-724.
83. Valentine J.L., Mayersohn M., Wessinger W.D., Arnold L.W., Owens S.M. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 1996, 278:709-716.
84. Proksch J.W., Gentry W.B., Owens S.M. Anti-phencyclidine monoclonal antibodies provide longterm reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000, 292:831-837.
85. Hardin J.S., Wessinger W.D., Wenger G.R., Proksch J.W., Laurenzana E.M., Owens S.M. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 2002, 302:119-126.
86. Pitas G., Laurenzana E.M., Williams D.K., Owens S.M., Gentry W.B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 2006, 34:906-912.
87. Laurenzana E.M., Gunnell M.G., Gentry W.B., Owens S.M. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 2003, 306:1092-1098.
88. Lacy H.M., Gunnell M.G., Laurenzana E.M., Owens S.M. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol 2008, 8:1-11.
89. Hubbard J.J., Laurenzana E.M., Williams D.K., Gentry W.B., Owens S.M. Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats. Int Immunopharmacol 2011, 11:2181-2187.